BUCOLOME

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H22N2O3
Molecular Weight	266.3361
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC1C(=O)NC(=O)N(C2CCCCC2)C1=O

InChI

InChIKey=DVEQCIBLXRSYPH-UHFFFAOYSA-N

InChI=1S/C14H22N2O3/c1-2-3-9-11-12(17)15-14(19)16(13(11)18)10-7-5-4-6-8-10/h10-11H,2-9H2,1H3,(H,15,17,19)

HIDE SMILES / InChI

Molecular Formula	C14H22N2O3
Molecular Weight	266.3361
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10497145
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18445991 and http://www.genome.jp/dbget-bin/www_bget?drug+D01661

Bucolome (Paramidine) is a barbiturate derivative. It is a non-steroidal anti-inflammatory drug, which is used in the treatment of chronic articular rheumatism. It has been used as a uricosuric and/or anti-inflammatory agent in Japan since 1967. Bucolome acts as a CYP2C9 inhibitor and reduces the metabolism of several commonly used drugs, which makes it useful for potentiating or extending the duration of action of those drugs, or reducing the production of unwanted metabolites.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 2C9 50 Target ID: CHEMBL3397 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10497145	Inhibitor 8297		8.24 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Rheumatoid arthritis 316 Sources: http://www.ncbi.nlm.nih.gov/pubmed/5632931	Palliative		Approved 8429	PARAMIDIN Approved Use Antirheumatic and antigout drug

PubMed

Title	Date	PubMed
Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome.	2005 Apr	15640375
[Intraluminal ureteral hematoma complicating anticoagulant therapy].	2005 Jul	16083035

Patents

Sample Use Guides

In Vivo Use Guide

300 mg dose of bucolome once a day

Route of Administration: Oral

In Vitro Use Guide

Protein binding of furosemide (20 M) was significantly inhibited by 300 M bucolome in human serum

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:30:22 GMT 2023` Edited by `admin` on `Fri Dec 15 16:30:22 GMT 2023`
Record UNII	9T08RAL174
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUCOLOME

Official Name

English

BUCOLOME [JAN]

Common Name

English

Bucolome [WHO-DD]

Common Name

English

2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-BUTYL-1-CYCLOHEXYL-

Systematic Name

English

5-N-BUTYL-1-CYCLOHEXYLBARBITURIC ACID

Common Name

English

BUCOLOM

Common Name

English

BUCOLOME [MI]

Common Name

English

5-BUTYL-1-CYCLOHEXYLBARBITURIC ACID

Systematic Name

English

bucolome [INN]

Common Name

English

BARBITURIC ACID, 5-BUTYL-1-CYCLOHEXYL-

Common Name

English

PARAMIDINE

Common Name

English

BUCOLOME [MART.]

Common Name

English

PARAMIDIN

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257